Skip to content

Author

D. D'Ardes

We have 5 of 123 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Review Oct 2026

Targeting Lipoprotein(a) in Cardiovascular Disease: Emerging Therapies and Clinical Implications.

Lipoprotein(a) [Lp(a)] is a genetically determined apolipoprotein B-containing lipoprotein independently associated with atherosclerotic cardiovascular disease (ASCVD) and calcific aortic valve stenosis (CAVS). Circulating Lp(a) concentrations are largely inherited, minimally responsive to lifestyle modification, and n...

C. Acierno, D. D'Ardes, A. Boccatonda et al. · 0 citations
Review Open access Sep 2026

Diaphragm Ultrasound: State-of-the-Art Review.

Diaphragm ultrasound has become a widely adopted bedside tool for assessing respiratory muscle function in both acute and chronic respiratory failure. Initially introduced as a descriptive imaging technique, it is now increasingly used to support physiological interpretation, prognostic evaluation, and monitoring durin...

Alice Brighenti, A. Boccatonda, D. D'Ardes et al. · 0 citations
Review Open access Sep 2026

From Adipose Tissue Dysfunction to Venous Thromboembolism

Background/Objectives: Obesity is a major modifiable risk factor for venous thromboembolism (VTE), driven by adipose tissue dysfunction, chronic inflammation, endothelial dysfunction, hypercoagulability, impaired fibrinolysis, immunothrombosis, and venous stasis. Modern incretin-based therapies induce substantial weigh...

Andrea Boccatonda, Alice Brighenti, Alfredo Caturano et al. · 0 citations
Review Open access Aug 2026

⁠From liver to cardiovascular system: the MASLD-ASCVD continuum.

Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease worldwide and is increasingly recognized as a systemic cardiometabolic disorder. Atherosclerotic cardiovascular disease (ASCVD) represents the leading cause of mortality in patients with MASLD. This review aims...

Andrea Boccatonda, Antonella Bray, M. Marozzi et al. · 0 citations
Review Open access Sep 2026

Immunometabolism in Obesity-Associated Type 2 Diabetes: Molecular Mechanisms and Emerging Therapeutic Targets

A narrative review synthesises mechanisms and examines how metformin, glucagon-like peptide-1 receptor agonists, sodium–glucose cotransporter 2 inhibitors and inflammasome-directed agents intersect with them in obesity-associated T2D.

C. Acierno, Massimiliano Cavallo, D. D'Ardes et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.